The global market for Small Molecule Active Pharmaceutical Ingredients (API) is projected to continue its growth trajectory, with sales expected to reach USD 120,376.6 million in 2024. According to the latest market report, the market is forecasted to reach a value of USD 186,941.2 million by 2034, reflecting a steady CAGR of 4.5% during the forecast period from 2024 to 2034.
Small molecule APIs, essential components in pharmaceutical manufacturing, are widely used in the production of various drugs, particularly for treating chronic and complex diseases such as cancer, diabetes, and cardiovascular conditions. The growing demand for these drugs, combined with ongoing advancements in drug development and manufacturing processes, is fueling the market’s expansion.
As the cases of these diseases such as cancer, diabetes, and cardiovascular conditions continue to rise globally, the need for effective and sustained therapeutic options also increases. Small molecule APIs will continue to play a central role in the treatment of chronic diseases because they easily interact with specific biological targets in the human body.
Most of these APIs are formulated into oral drugs, which are convenient for long-term medication administration. Furthermore, since many chronic diseases require combination treatments to have an effect on different aspect of the condition, the requirement for various small molecule APIs increases.
As a result, with this increased demand, the global small molecule API market gets driven due to increased continuous research, development, and production in order to meet the growing health needs.
Technological advances in API manufacturing have significantly supported the growth of the small molecule API industry. Innovation in chemical synthesis enables manufacturing processes that deliver APIs in an economical way, at a high yield and in a good level of purity. This reduces the cost of production, whereby the manufacturing processes become scalable or flexible in line with a growing global demand.
Key Takeaways from the Report:
- Growing Demand for Small Molecule Drugs
The increasing global prevalence of chronic diseases and the continuous need for effective treatments are key drivers of the market for Small Molecule APIs. As more pharmaceutical companies focus on developing small molecule drugs for targeted therapies, the demand for these APIs is expected to rise. - Innovation and Advances in Drug Development
Ongoing advancements in drug discovery and the rising number of drug approvals for small molecule therapies are contributing to the growth of the market. These therapies are preferred due to their ease of production, cost-effectiveness, and versatility in treating a wide range of diseases. - Market Growth in Emerging Economies
As healthcare infrastructure improves in emerging markets, the demand for pharmaceutical products, including Small Molecule APIs, is expected to surge. The increasing availability of healthcare services and rising awareness of health conditions is creating new opportunities for API manufacturers. - Y-o-Y Growth and Strong Performance in 2024
The Small Molecule API market is anticipated to exhibit a Y-o-Y growth of 4.6% in 2024, indicating a positive outlook for the industry. This growth is supported by the strong demand for small molecule drugs and the continuous expansion of pharmaceutical production capacities worldwide. - North America and Asia-Pacific Drive Market Dynamics
North America holds a significant share of the market due to the presence of major pharmaceutical companies and strong demand for APIs. Meanwhile, the Asia-Pacific region is expected to witness substantial growth due to increasing pharmaceutical manufacturing activities, cost-effective production capabilities, and rising healthcare investments.
Competitive Landscape
The small molecule API market is highly fragmented. There are large number API manufacturer in the global market involved in developing novel products so that they can meet their customer’s needs.
Prominent producers of Small Molecule API products are concentrating on growing internationally in order to increase their revenue and increase the size of their sales footprint in developing nations through the purchase of regional competitors. Manufacturers utilize various key strategies such as agreements, product launches, research sponsorship, and strategic collaborations to boost product sales and establish their market presence.
Recent Industry Developments in Small Molecule API Market:
- On April 4, 2024, Odyssey Therapeutics, Inc., a biotechnology company, announced that they have entered into a strategic research collaboration with Johnson & Johnson Company, to jointly discover and optimize small molecule medicines against select therapeutic targets.
- On January 31, 2024, Teva Pharmaceutical Industries Ltd, an Israel-based multinational pharmaceutical company, announced the intent to divest their small-molecule active-pharmaceutical ingredient (API) business, or “TAPI”.
Key Players of Small Molecule API Industry
- Johnson Matthey
- Pfizer Inc.
- Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd.
- Sanofi S.A
- Novartis AG
- Bristol-Myers Squibb
- Boehringer Ingelheim GmbH
- GlaxoSmithKline PLC
- GILEAD Sciences Inc.
- Albany Molecular Research Inc.
- AstraZeneca
- Merck & Co. Inc.
- BASF SE
- Teva Pharmaceuticals
- Hoffmann-La Roche Ltd.
A Comprehensive Full Report
Key Segments of Small Molecule API Industry
By Molecule Type:
In terms of molecule type, the industry is divided into standard API and HPAPI
By Production:
In terms of production, the industry is segregated into captive/in-house and outsourced
By Application:
In terms of application, the industry is divided into clinical and commercial.
By Therapeutic Area:
In terms of therapeutic area, the industry is segregated into cardiovascular diseases, respiratory disorders, infectious diseases, metabolic disorders, oncology, immunology, neurology, urology, dermatology, ophthalmology, general health and others
By End User:
In terms of end user, the industry is segregated into pharmaceutical companies, biotechnology companies and CRO & CDMO
By Region:
Key countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
